Plain answers on every compound we make: what it is, how it works, what the published research actually covers, and where it stands in Australia. Written by the lab team, cited, and kept honest about what is early-stage.
Message us and ask. We make everything we sell, so the person answering can tell you what a batch tested at and what the published research does and does not show.
These guides summarise published research for educational purposes. They are not medical advice. OzPeptides products are sold for research and laboratory use only, not for human consumption. 18+ only.
Every compound we make has a guide, and each one answers the question a person actually types — what is BPC-157, is retatrutide approved in Australia, is TB-500 the same as thymosin beta-4. A guide that repeats the same paragraph with the name swapped is worth nothing to a reader, so each is written from the compound's own literature and says something true only of that compound.
The framing is research throughout. No dosing protocols, no therapeutic claims, no before-and-after photographs. These are laboratory compounds and the guides treat them as such, which is also why they carry arithmetic, batch testing detail and citations rather than promises.
Sources are listed per compound. Where a claim rests on a single paper from a single group, the guide says so.
A research library that presents every compound as promising is useless, because the reader learns nothing from it. The evidence in this catalogue varies enormously, and the guides say where each one sits.
Some examples. Retatrutide has no completed phase 3 trial anywhere. AOD-9604 reached phase 2b in obesity and did not separate from placebo on its primary endpoint. BPC-157 has hundreds of papers and no identified receptor. DSIP is named for a sleep effect that largely failed replication. Epithalon's telomerase claim has not been reproduced by unaffiliated laboratories. Cerebrolysin has a large trial literature that Cochrane reviewers found insufficient to support routine use.
Stating those things costs nothing and is the reason to trust the rest. Where evidence is genuinely strong — semaglutide's cardiovascular outcome data, kisspeptin's human genetics, afamelanotide's registration — the guides say that too.
A handful of the molecules here exist as registered prescription medicines in Australia under brand names — semaglutide, tirzepatide, oxytocin and hCG among them. That is a different thing from being an approved research chemical, and the distinction is worth holding: a registered product is a specific formulation made to pharmaceutical standards with a regulator behind each batch.
Research-grade material of the same molecule is a laboratory reagent and not a substitute for a prescription medicine. Nothing else in the catalogue is registered in Australia, and several compounds — the melanotan peptides in particular — carry well-documented safety concerns. Each guide says which applies.
For athletes, the guides state anti-doping classification where it exists. BPC-157 sits under WADA S0, TB-500 and the growth hormone secretagogues under S2, and hCG is listed sex-specifically. Compounds with no human therapeutic approval anywhere fall under S0 whether or not they are named.
Start with the compound guide if you want to know what something is and what is established about it. Each carries a quick answer, a facts table, sections answering the common questions, per-compound FAQs and sources.
Use the comparison guides when the question is which of two or three — retatrutide against tirzepatide and semaglutide, BPC-157 against TB-500, MT-1 against MT-2, GHK-Cu against AHK-Cu. Those pages carry the rows where the answer genuinely differs, which is the only kind of comparison row worth writing.
Use the reconstitution calculator for the arithmetic: concentration, volume per draw, units on a 100-unit syringe, and how many draws a vial holds. It is pre-filled per product rather than generic, and it gives no dosing guidance because that is not a supplier's place.
They are written in-house from each compound's published literature, with sources listed per guide. Where a claim rests on a single group's work, the guide says so.
No. These are laboratory research compounds. The guides carry vial arithmetic, evidence summaries and regulatory status, not protocols.
A few exist as registered prescription medicines under brand names — semaglutide, tirzepatide, oxytocin, hCG. Research-grade material of the same molecule is a laboratory reagent, not that product.
Because for some compounds it is. A library that presented everything as promising would teach the reader nothing, so each guide states where its compound actually stands.